These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3733227)

  • 1. Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.
    Rolston KV; Bodey GP
    Infection; 1986; 14(3):139-41. PubMed ID: 3733227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefpirome susceptibility in staphylococci isolates.
    Poiată A; Tuchiluş C; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(1):276-9. PubMed ID: 17595881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.
    Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1986 Jan; 4(1):53-63. PubMed ID: 3632921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
    Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
    J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activity of cefpirome against bacteria isolated from hospitalized patients].
    Fernández A; Herran I; de Mier C; Marcenac FM
    Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
    Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
    Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
    Kayser FH
    Eur J Clin Microbiol; 1987 Jun; 6(3):309-12. PubMed ID: 3497804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.
    Ritchie DJ; Hopefl AW; Milligan TW; Byrne JE; Maddux MS
    Clin Ther; 1993; 15(1):107-13. PubMed ID: 8458040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci.
    Raymond J; Vedel G; Bergeret M
    J Antimicrob Chemother; 1996 Dec; 38(6):1067-71. PubMed ID: 9023655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus.
    Swenson JM; Tenover FC
    J Antimicrob Chemother; 2002 May; 49(5):845-50. PubMed ID: 12003982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.